Guidant To Push DES Program In 2005, Says Champion Fracture Issue Solved
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects to launch its Champion everolimus drug-eluting stent in Europe in mid-2005, assuming regulators agree that the firm has resolved stress fracture problems related to the device
You may also be interested in...
Third Quarter 2004 Earnings In Brief
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...
Third Quarter 2004 Earnings In Brief
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...
Guidant Awaits SPIRIT Trial Data For Clear Vision Of Future Stent Business
Feasibility data on the Multi-Link Vision cobalt-chromium, durable-polymer, everolimus-eluting stent will be key to predicting the stability of Guidant's DES technology platform in the post-Dollens era